CHF 60.00 pre-market: DKSH Holding AG (DKSH.SW, SIX) earnings spotlight on 12 Feb 2026

DKSH.SW stock opens pre-market at CHF 60.00, down -1.20 (‑1.96%) after a prior close of CHF 61.20 as investors position ahead of earnings on 17 Feb 2026. The Zurich-listed DKSH Holding AG (SIX: DKSH.SW) shows a 50-day average of CHF 57.51 and a 200-day average of CHF 58.41, signalling recent strength but limited near-term upside. With EPS CHF 3.00 and PE 20.27, the upcoming report matters for dividend safety and margins in Healthcare and Consumer Goods.

DKSH.SW stock: Pre-market snapshot and immediate drivers

DKSH.SW stock trades pre-market at CHF 60.00 with a day low of CHF 59.00 and day high of CHF 60.10. Volume is 75,822.00 versus an average of 95,266.00, so liquidity is normal for this phase. Investors cite the earnings date on 17 Feb 2026 as the key near-term catalyst that could widen intraday moves and affect the 3.87% dividend yield.

DKSH.SW stock earnings preview: what to watch on 17 Feb 2026

The market will focus on margin trends in Healthcare and Consumer Goods and on working capital given DKSH’s distribution model. Consensus expectations are thin publicly, so management commentary on revenue mix and receivables days will be decisive. DKSH.SW earnings will also inform dividend credibility given the payout ratio 78.10% and dividend per share of CHF 2.35.

DKSH.SW stock valuation and financial metrics

DKSH.SW trades at PE 20.27 with EPS CHF 3.00 and market cap CHF 3,951,075,901.00. Key ratios: PB 2.40, Price/Sales 0.35, and Free Cash Flow yield 7.28%. Return on equity is 11.26% and debt-to-equity is 0.45, showing moderate leverage. These metrics support a base fair value near current levels using a PE band approach.

DKSH.SW stock technicals and trend signals

Technicals show momentum but limited trend strength: RSI 66.21 and CCI 144.43 point to near-term overbought conditions. Price sits above the 50-day average CHF 57.51 and 200-day average CHF 58.41, supporting the recent uptrend. ATR is 1.04, so expect intraday swings around CHF 1.04 on earnings volatility.

DKSH.SW stock risks and opportunities

Risks: slower growth in Greater China or Thailand, margin compression in Performance Materials, and receivables build given days-sales-outstanding 58.06. Opportunities: stable dividend yield 3.87%, improved Healthcare product mix, and cost leverage if volume recovers. Sector context: Swiss Industrials have outperformed some sectors YTD, but Industrials show mixed momentum.

DKSH.SW stock: Meyka AI grade and forecast

Meyka AI rates DKSH.SW with a score out of 100: 71.24, Grade B+, Suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of CHF 59.01 and a yearly price of CHF 52.65. Compared with the current price CHF 60.00, the model implies a monthly downside of -1.65% and a yearly downside of -12.25%. Forecasts are model-based projections and not guarantees. For more details visit DKSH on Meyka and background reporting at Bloomberg profile.

Final Thoughts

Earnings on 17 Feb 2026 are the immediate pivot for DKSH.SW stock. At CHF 60.00, the shares reflect a mix of modest growth and a reliable dividend CHF 2.35. Valuation metrics—PE 20.27, PB 2.40, and Free Cash Flow yield 7.28%—point to fair value near current levels, but Meyka AI’s yearly model projects CHF 52.65, implying -12.25% downside from today. Traders should expect heightened volatility with ATR CHF 1.04 and watch margin commentary, receivables trends, and regional sales. Our price target framework: conservative CHF 51.00, base CHF 60.00, bull CHF 72.00. These are guides, not guarantees. Meyka AI-powered market analysis flags the stock as a tactical BUY given balance-sheet strength and dividend income, but earnings execution will determine direction.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.